It’s “goodwill toward all” season, right? So now is the time to get ready to be nice to yourself. I don’t know whether this trade war will end, or if impeachment will lead to something bigger, or whether President Trump will find a way to goose the stock market again next year to boost his […]
Articles
This week brought yet another push-pull to the markets as investors attempt to figure out whether Lucy is going to pull the football away from Charlie Brown again in the China trade talks, but the narrative that struck me as most interesting on the week was the line that was drawn in the economy by […]
My experience in digging through these teaser ads over the past dozen years tells me that the super-expensive “premium” newsletters are no more likely to generate long-term returns than the “entry level” newsletters… but we’re conditioned to associate price with value, and $5,000 newsletters are simply out of reach for so many small investors, so […]
I’ve heard Chris Mayer talk about his “Coffee Can” strategy before, but this new way that Agora is marketing it caught my eye: “Investing tips for the couch potato “This has got to be the laziest investment strategy out there today. “Imagine investing in stocks and coming back 10 years later to discover your money […]
Chris Mayer runs the Capital and Crisis newsletter, often looking for far-flung stocks or odd special situations, and he sometimes brings an interesting idea or two to us through his teaser pitches … so I thought we’d take a look at his latest idea today, a spiel about some stocks that you can buy and […]
Whitney Tilson had a good update presentation on some of his ideas this morning — nothing earth-shaking, and not much “new” news beyond what he shared during our pre-conference seminar yesterday or in past conferences, but he did reiterate his pitch that Berkshire Hathaway remains a ridiculous bargain, he now puts roughly a 12 PE […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
Check out the Moderna Aug 11, 2020 8-K filing: "The U.S. Supply Agreement provides for the manufacturing and delivery ...
Cytodyn will be reporting on P2 M2M results within 2 weeks, and DSMC is taking a look at their S/C P2b/P3 trial this wee...
Yes, there is the small possibility that a vaccine could make your reaction to the pathogen worse. That's one of the th...
I'm surprised you didn't bring up leronlimab. Mark this note....it will be the leading therapy for COVID-19 in short or...
Regarding C19 treatments, one you should keep your eye on is Leronlimab from Cytodyn, a small cap pharma. A BLA for HIV...
Agreed... My money is on CYDY for HIV and cancer, but C19 trials are eye opening.... This coming week will tell the tail...
In 1979 I began college for a pharmacy degree. My father in law was an emeritus professor at University of Michigan sch...
CEO of Co-Diagnostics $CODX was on Varney (FBN) on 3/5 mentioning the fact that recent relaxation of FDA restrictions no...
Headline from 3/1: Vaxart, Inc. (NasdaqGS: VXRT), a clinical-stage biotechnology company developing oral recombinant vac...
TOMZ recent headline: https://finance.yahoo.com/news/steramist-declared-official-decontamination-technology-143010170.ht...
Just some ideas: "CODX", maker of diagnostic kits for Covid-19 could go vertical once approved by FDA/CDC. The stock ha...
Great and informative article from a medical prospective. What stocks do u all think will rally, even if temporarily, du...